McLoughlin Margaret 4

What Happened

• Margaret McLoughlin, a director of Quince Therapeutics, was granted a derivative award on 2026-01-02 covering 19,547 shares reported at $0.00. The award was elected in lieu of her annual outside director cash retainer for 2026. This is a compensation grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-01-02; filing date (Form 4): 2026-01-21 (filed ~19 days after the transaction).
• Amount: 19,547 shares (derivative/option award); reported acquisition price: $0.00 on the Form 4.
• Vesting: Shares subject to the option vest in equal quarterly installments over one year (per footnote).
• Reason: Reporting person elected to receive stock options instead of the 2026 outside director cash retainer.
• Shares owned after transaction: Not specified in the information provided in this summary.
• Timeliness: Filing appears late relative to the standard Form 4 deadline (filed well after the typical 2-business-day window).

Context

• This was a routine director compensation award rather than a market purchase or sale; such grants are common for outside directors and reflect compensation choices, not necessarily a direct market sentiment signal.
• The award is a derivative (option) with a stated vesting schedule. The Form 4 shows $0.00 for the acquisition price, which is typical reporting for option grants on Form 4; consult the company’s equity award agreements or proxy/SEC filings for exercise price and other terms.